AMAG Pharmaceuticalsの推定成長EPS Q/Q

AMAG Pharmaceuticalsの推定成長EPS Q/Qは何ですか。

AMAG Pharmaceuticals, Inc.の推定成長EPS Q/Qは-114.29%です。

推定成長EPS Q/Qの定義は何ですか。



期待される四半期ごとのEPS成長率は、過去四半期の業績と比較して、次の四半期の企業EPSの推定増加です。

The prospective EPS growth rate is a predicted estimate of the earnings per share growth rate towards the current quarter and expressed as a percentage compared to the respective past quarter. The estimated earnings per share growth rate is an important factor for judging a company's value. Comparing EPS history with stock price history helps determine the most likely future direction of the stock price.

Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.

NASDAQのセクタHealth Careにおける推定成長EPS Q/Qの企業と比べるAMAG Pharmaceuticals

AMAG Pharmaceuticalsは何をしますか。

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. The firm focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. Its products include Intrarosa, Vyleesi, Makena, CBR, Feraheme, and MuGard. The company was founded on November 9, 1981 and is headquartered in Waltham, MA.

AMAG Pharmaceuticalsと類似の推定成長eps q/q